








WHY SWISS BRIDGE

What sets us apart from the rest in the field of cancer research?
It is the extremely positive feedback we continuously receive from all our partners:

-  Distinguished reputation of the SWISS BRIDGE Award
-  Identification of specific projects in Switzerland and in other countries
-  Professional scientific jury
-  Designated donations are made available in full to screened and selected cancer researches & projects
-  Low cost for advertising, PR, IT and fees, covered by supporters & friends of the foundation

This unique concept enables us to look to the future with optimism and take another important step in the fight against cancer!

Donations: Credit Suisse · 8070 Zurich · IBAN: CH52 0483 5095 7385 1100 0

JUBILEE GOLF EVENT 2022

Golfclub Lenzerheide, 31st August 2022

It was another glorious day of golf and a wonderful evening.

Many thanks to everyone who turned up to the loyal sponsors and friends of SWISS BRIDGE for their great support of this event.



SAVE THE DATE:

SWISS BRIDGE GOLF EVENT 2023 · 23rd August 2023 · Buna Vista Golf Sagogn



ORGANIZATION

Board of Foundation

Prof. Dr. Jakob Passweg (Chairman)
Eleonore E. Droux, Herrliberg
Dr. Thomas Peter, Küsnacht
Yves Monnard, Zurich
Liv Bahner, Zurich

Founder of Foundation

Thomas Hoepli, Lenzerheide

Honory Chairman

Prof. Dr. Giorgio Nosedà

Scientific Jury

Prof. Dr. Adrian Ochsenbein (Chairman)

Management

Philipp Lücke (CEO)

Board of Patrons

Dr. med. Jaques Bernier, Geneva
Prof. Dr. med. Dr. h.c. Urs Metzger, Zurich
Sir Paul Nurse, London
Heinz Roth, Uitikon/ Waldegg
Prof. Dr. med. Thomas Szucs, Zollikon

Administration

SWISS BRIDGE Foundation
P.O. Box 1556, 8027 Zurich
Phone + 41 (0) 43 31 71 360
info@swissbridge.ch



www.swissbridge.ch



SPECIAL EDITION SWISS BRIDGE AWARD 2022

Zurich, December 2022

Cancer and Infection: Half a Million Swiss Francs for two research projects



Prof. Dr. Adrian Ochsenbein (Chairman Scientific Jury), Dr. Michal Bassani-Sternberg, Dr. Sylvain Peugeot, Prof. Dr. Jakob Passweg (President), Philipp Lücke (CEO)

Zurich, 26 October 2022 – Two research scientists from Switzerland and Sweden have received the SWISS BRIDGE Award 2022 for their research projects on infection-related cancers.

The awarded sum of 250'000 Swiss francs each will be invested in the implementation of their promising projects. Infections with certain viruses and bacteria, such as the human papillomavirus (HPV) or Helicobacter pylori, are considered risk factors for the development of cancer. Worldwide, they are responsible for about 15% of all cancer cases; in low- and middle-income countries even for up to 30% of all cases.

However, not every infected person develops cancer, but it is still poorly understood why this is so. To prevent or better treat more infection-related cancers in the future, further research is therefore urgently needed. For this reason, the SWISS BRIDGE Foundation has decided to dedicate the 2022 SWISS BRIDGE Award to the topic of infections and cancer. A total of 32 young scientists from all over Europe applied for the award this year.

In a two-stage evaluation process, a scientific jury of distinguished experts gave priority to two research projects. The main investigators, Michal Bassani-Sternberg from the CHUV University Hospital in Lausanne and Sylvain Peugeot from the Karolinska Institutet in Stockholm, have each been awarded 250'000 Swiss francs to be invested in the realization of their research projects.



Michal Bassani-Sternberg

MD PhD Oncology

University Hospital of Lausanne
Centre de recherche
Agora Rue du Bugnon 25A
CH-1011 Lausanne

Project title:
Oncovirus-derived antigen discovery in human tumors for development of novel antigen-enriched and personalized adoptive T cell therapy



Sylvain Peuget

MD PhD
Microbiology

Tumor and Cell biology (MTC)
Karolinska Institutet
Biomedicum, C8 Tomtebodavägen
16 SE-171 65 Solna
Sweden

Project title:
Exploring the links between oncogenic bacteria and cancer for innovative therapies



In quest of viral antigens

Michal Bassani-Sternberg and her team have been working on the development of personalized immunotherapies against cancer. Their research is based on tumor antigens, which are presented on the surface of cancer cells and can be recognized as foreign by the immune system.

In the award-winning project, the team is focusing specifically on the antigens of viruses such as Epstein-Barr virus, human papillomavirus and Merkel Cell Polyomavirus, which are associated with the development of lymphoma, cervical cancer, Merkel Cell Carcinoma (a rare but aggressive form of skin cancer) and other types of cancer. First, the researchers plan to precisely determine the protein fragments of the individual viruses. They will be displayed as antigens on infected cancer cells. Subsequently, they would like to identify special defense cells of the immune system - T cells - that have specific receptors and can recognize the viral antigens.

Once identified, these T cells can be developed into advanced immunotherapies.




WANT TO SUPPORT THIS PROJECT?
WE LOOK FORWARD TO HEARING FROM YOU.

Sylvain Peuget and his team will investigate the role that certain bacteria in our intestinal flora play in the development and progression of colorectal cancer. Their work focuses on a tumor suppressor gene p53, which normally prevents healthy cells from becoming cancer cells.

The researchers hypothesize, that certain bacteria in the intestine are able to disrupt the function of p53 and thus promote the development of colorectal cancer. The goal of the research project is to characterize these harmful bacteria in more detail and to determine the signaling pathways through which they regulate p53.

A better understanding of these mechanisms may help to find new ways to treat colorectal cancer, either by targeting the cancer cells directly or by targeting the cancer-promoting bacteria.

Better understanding of how cancer-promoting bacteria work



WANT TO SUPPORT THIS PROJECT?
WE LOOK FORWARD TO HEARING FROM YOU.

